Sutura, Inc.
OTC Bulletin Board : SUTU

Sutura, Inc.

September 20, 2005 11:09 ET

SuperStitch Developer Sutura Hires Key Sales Representatives

FOUNTAIN VALLEY, CALIFORNIA--(CCNMatthews - Sept. 20, 2005) - Sutura®, Inc. ("Sutura") (OTCBB:SUTU), a California-based medical device company, announced today it has added three new veteran sales representatives to its expanding national SuperStitch sales force. These experienced vascular product sales representatives bring a wealth of knowledge and contacts within the southeastern region of the country and have a combined 17 years experience selling competitive devices in that area.

Joining Sutura's SuperStitch sales team are Kevin Cummings, Brad Raburn and Ken Teter. Brad Raburn will operate his territory out of Shreveport, Louisiana with Ken Teter based in Alabama. Kevin Cummings will represent Sutura in the southeast from Washington, DC.

"We expect to see immediate results as these seasoned sales professionals begin calling on their customers with the SuperStitch device," stated Tom Lindsey, Director of U.S. Sales and Marketing for Sutura. "It is a clear advantage to have such well-connected Sales Reps within a given area. Given their level of previous experience with similar medical device products and their customer base, we expect to see a rapid and accelerated learning curve for these and other reps we are currently in negotiations to hire. Our goal is to have sales representation in all major markets of the country within the next 30 days."

About Sutura, Inc.

Sutura®, Inc. (www.suturaus.com) is a medical device company that has developed a line of innovative, minimally invasive, vascular suturing devices to suture the puncture created in arteries during open surgery and catheter-based procedures. The Company's line of SuperStitch medical devices provide sutured closure of the arteriotomy site utilizing the existing catheter sheath introducer or cannula during fluoroscopically guided procedures and directly through the open arteriotomy during open surgical procedures.

Within the United States the F8 & F6 SuperStitch device has been cleared by the FDA under section 510(k) of the Federal Food, Drug, and Cosmetic Act ("FDC Act") for use in performing vascular stitching in general surgery, including endoscopic procedures. It is not intended for blind closure of an arteriotomy site. The SuperStitch F8 & F6 is approved in the European Union and CE marked with the indication for use as follows: The SuperStitch is indicated for use in performing vascular stitching in general surgery, including endoscopic procedures. In the EU there is no requirement for the use of fluoroscopic guidance. Sutura's headquarters are in Fountain Valley, California. "Sutura®" and "SuperStitch®" are registered trademarks of Sutura, Inc.

Forward-Looking Information Is Subject to Risk and Uncertainty

Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may", "appears", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the acceptance of the SuperStitch® devices by medical providers and the marketplace in general and the success of the proposed marketing plan, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.

Contact Information

  • Sutura, Inc.
    Barry Forward
    Corporate Communications
    (866) 676-8386
    www.suturaus.com